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DIALYSIS–TRANSPLANTATION
Antiphospholipid antibodies as a risk factor for atherosclerotic
events in renal transplant recipients
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Antiphospholipid antibodies as a risk factor for atherosclerotic
events in renal transplant recipients.
Background. Epidemiologic studies reported that antiphos-
pholipid antibodies (APAs) were independent predictors of
atherosclerotic events. We recently reported a high prevalence
of APAs in renal transplant recipients. Nevertheless, the role
of APAs on atherosclerotic events has not been prospectively
studied in this high-risk population.
Methods. Participants in the study were 324 consecutive re-
nal transplant recipients. Patients were enrolled between Janu-
ary 1996 and May 1998 and followed up until June 2002.
Results. The patients were followed for a mean duration of
62  26 months. Eighty seven (26.8%) patients exhibited
APAs. We found a slight, but significant, correlation between
total plasma homocysteine (tHcy) concentration and anticardi-
olipin (ACA) titers (r 0.26; P 0.036). Fifty six athersclerotic
events (17.2%) occurred in 54 patients. Atherosclerotic events
occurred more frequently in patients with APAs (33% vs. 9%;
P  0.0003) and ACAs levels were higher in patients who
experienced atherosclerotic events (23.7  13.1 IU vs. 13.9 
9.4 IU; P  0.003). APAs were associated with an increased
risk of atherosclerotic events (RR, 2.82; 95% CI, 1.17 to 5.31).
Cox regression analysis also revealed that age above the median
(RR, 5.21; 95% CI, 1.67 to 17.13), a previous history of cardio-
vascular disease (RR, 3.54; 95% CI, 1.57 to 10.43), hyperhomo-
cysteinemia (RR, 4.01; 95% CI, 1.22 to 14.61), and current
smoking (RR, 2.17; 95% CI, 1.01 to 6.72) were risk factors for
atherosclerotic events.
Conclusion. The presence of APAs is an independent car-
diovascular risk factor in renal transplant recipients. Prevention
trials are necessary to assess the efficacy and safety of anticoag-
ulation therapy in transplant patients with APAs.
Antiphospholipid antibodies (APAs) are a heteroge-
neous group of immunoglobulins (Igs) directed against
negatively charged phospholipids, protein-phospholipid
complexes, or plasma proteins such as -glycoprotein I
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(2-GPI) [1]. APAs include anticardiolipin (ACA) and
lupus anticoagulant (LAC) antibodies. The former are
recognized by their ability to bind to anionic phospholip-
ids in solid-phase immunoassays and the latter cause pro-
longation of phospholipid-dependent coagulation tests [1].
Recent experimental data suggest that APAs may inter-
fere with atherogenic process. APAs can crossreact with
antioxidized low-density lipoprotein (LDL) antibodies
[2], enhance the uptake of oxidized LDL macrophages [3],
and promote thrombosis [4]. However, some epidemio-
logic studies reported that APAs were independent pre-
dictors of atherosclerotic events [5–9]. Nevertheless, some
other studies have not confirmed these results [10–13].
Stable renal transplant recipients have disproportion-
ately high rates of arteriosclerotic outcomes [14]. An
increased prevalence of traditional cardiovascular risk
factors cannot fully explain this increased incidence of
athersclerotic events in the transplant population [15]
and the role of nontraditional cardiovascular risk factors,
such as hyperhomocysteinemia, has been recently em-
phasized [16]. We recently reported a high prevalence
of APAs in renal transplant recipients [17]. Nevertheless,
the influence of APAs on atherosclerotic events has not
been prospectively studied in this high-risk population.
We postulated that APAs may play a role in the pro-
gression of atherosclerosis in renal transplant recipients
and so prospectively examined the association between
APAs and atherosclerotic events in an unselected popu-
lation of renal transplant recipients.
METHODS
Patient characteristics
The aim of the study was to evaluate the influence of
APAs on cardiovascular disease in renal transplant recipi-
ents. Participants in the study were 324 consecutive renal
transplant recipients (178 previously reported renal trans-
plant recipients who participated in a previously reported
study on the prevalence of APAs in renal transplant
recipients [17] and 146 consecutive additional renal trans-
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plant recipients followed up in our unit). Patients were
enrolled between January 1996 and May 1998 and fol-
lowed up until June 2002. Patients with a past diagnosis
of systemic lupus erythematosus (SLE) or primary anti-
phospholipid syndrome were excluded.
Cardiovascular risk factors
Age, gender, blood pressure, hemodialysis duration
before transplantation, diabetes mellitus, smoking status,
past history of cardiovascular events (atherosclerotic
events), immunosuppressive treatment, and different bi-
ologic parameters were assessed at inclusion.
Past history of atherosclerotic events
A past history of atherosclerotic event was defined by
(1) coronary heart disease, including myocardial infarc-
tion; coronary revascularization, including coronary artery
bypass surgery or percutaneous transluminal coronary an-
gioplasty; typical history of angina with abnormal coro-
narography or myocardial scintigraphy; (2) stroke/cere-
brovascular disease, including nonhemorrhagic strokes;
carotid endarterectomy; and (3) abominal aortic or lower
extremity arterial disease, including abdominal aortic
repair; lower extremity amputation; or intermittent clau-
dication confirmed by Doppler or arteriography findings.
Smoking behavior
With respect to smoking behavior, subjects were cate-
gorized as current smokers or nonsmokers.
Blood pressure
Blood pressure was measured using a semiautomatic
device, based on an oscillometric method with the pa-
tients in a sitting position after resting more than 5 min-
utes. Hypertension was defined by a systolic blood pres-
sure140 mm Hg or a diastolic blood pressure90 mm Hg
or any antihypertensive treatment.
Lipid profile
Triglycerides, and total and high-density lipoprotein
(HDL) cholesterol concentrations were measured. LDL
cholesterol was calculated using the method described
by Friedwald. Hyperlipidemia was defined by a LDL
cholesterol1.6 g/L or triglycerides2 g/L or any hypo-
lipemiant treatment.
APAs
Venous blood (9 volumes) was collected by clean veni-
puncture into plastic tubes containing 0.13 mol/L tri-
sodium citrate (1 volume) and high-speed centrifuged or
filtered through 0.2 mmol/L screens to remove platelets.
LAC was assayed with the following coagulation tests:
standard activated partial thromboplastin time and kaolin
clotting time. The results were expressed as ratios of the
clotting time of patient’s plasma to the clotting time of
normal pooled plasma and considered abnormal when
the ratio exceeded 1.2. Diagnosis of LAC was established
according to the recommended criteria: (1) prolongation
of at least one phospholipid-dependent clotting test; (2)
persistent abnormality (ratio patient/normal1.2) of the
test(s) after 1:1 mixing of patient’s plasma with normal
pooled plasma; and (3) modification of the clotting time
on changing the phospholipid concentration.
ACAs were measured with a sandwich enzye-linked im-
munosorbent assay (ELISA) procedure. Wells of ELISA
plates were coated by the addition of 30 L/well of 50
g/mL cardiolipin in ethanol, and the ethanol evapo-
rated at 4C overnight. Plates were washed with phos-
phate-buffered saline (PBS) and blocked by addition of
75 L/well of 10% adult bovine serum in PBS. After
blockade, the plates were washed with PBS. After addi-
tion to wells, the diluted serum samples and standard
were incubated for 1 hour. After washing, alkaline phos-
phatase-labeled, affinity-purified goat anti-human IgG
or IgM was added. After incubation, 50 L/well p-nitro-
phenyl phosphate diethanolamine was added. The en-
zyme reaction was stopped with 3 N NaOH. Spectropho-
tometric evaluation indicated the presence or absence
of ACA antibodies. Results were obtained by reading
the absorbance in a spectrophotometer. Dividing the
concentration value of the calibrator serum by the mean
absorbance value of that calibrator provided a conver-
sion factor. The absorbance values of the samples were
multiplied by the conversion factor to obtain ACA anti-
body concentrations in standard units. Values were ex-
pressed as glycophospholipid (GPL) units and consid-
ered positive when 23 GPL units. Both ACA IgG and
ACA IgM were determined. LAC and ACA positivity
was accepted only if confirmed on a different sample
collected after at least 4 weeks.
Homocysteine
Total plasma homocysteine (Hcy) was measured using
a previously described method [2]. Briefly, venous blood
samples were drawn after an overnight fast. The blood
sample was centrifuged within 15 minutes, and plasma
stored frozen at –20C. Hcy concentration, the sum of
the acid-soluble (that is reduced Hcy, homocysteine, di-
sulphide, and homocysteine-cysteine mixed disulphide),
and protein-bound moieties was measured by high-perfor-
mance liquid chromatography (HPLC). This assay in-
volves the following steps: reduction of the sample with
tri-n-butylphosphine, precipitations of proteins, alkalin-
ization of the supernatant with sodium borate, derivitiza-
tion with 7-fluoro-2-oxa-1,3 diazole-4 sulphonate, fol-
lowed by 8-aminonaphtalene-1,3,6-trisulphonic acid, and
HPLC separation with fluorescence detection. The nor-
mal values of plasma Hcy concentration ranged from 7
to 15 mol/L. The precision of the assay corresponds to
a coefficient of variation 3%.
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C-reactive protein
C-reactive protein was measured by nephelometry
(Beckman Coulter, Fullerton, CA, USA).
Renal function
Serum creatinine concentration and urinary protein
excretion were measured. Creatinine clearance was cal-
cultated using the Gault-Cockcroft formula.
Atherosclerotic events
Coronary heart disease. Myocardial infarction was doc-
umented by serial 12-lead electrocardiogram evidence or
Q wave infarction and appropriate myocardial enzyme
elevations; coronary revascularization, including coro-
nary artery bypass surgery or percutaneous transluminal
coronary angioplasty; or typical history of angina with
abnormal coronography.
Stroke/cerebrovascular disease. Nonhemorrhagic strokes
were confirmed by neurologic examination findings con-
sistent with new onset focal neurologic deficits, with or
without computed tomography (CT) or magnetic reso-
nance imaging (MRI) evidence of cerebral infarction;
or symptomatic extracranial artery stenosis resulting in
carotid endarterectomy.
Abdominal aortic or lower extremity arterial disease.
These conditions were documented by abdominal aortic
repair; lower extremity revascularization via bypass sur-
gery or angioplasty; lower extremity amputation; new
onset of intermittent claudication confirmed by Doppler
or arteriography findings.
Two physicians independent of the study were respon-
sible for atherosclerotic events ascertainment. This anal-
ysis was performed without knowledge of baseline char-
acteristics.
Statistical analysis
Arithmetic mean was calculated and expressed as SD.
Using log rank tests on Kaplan-Meier nonparametric
estimates of the survival without atherosclerotic events
distribution, we selected variables with a P value lower
than, or equal to, 0.20. The selected variables were in-
cluded into a Cox proportional hazards model, and a
backward stepwise selection process was performed, this
time at a classical   0.05. The time elapsed since kidney
transplantation was found to vary between patients;
therefore, this duration was forced into the Cox model
as a covariate. Age was split into two classes separated
by the median age (age  51 years). Gender and age
being potential confounding variables, they were also
entered into the Cox model, no matter the significance
of their relationships with atherosclerotic events. APAs
were tested as present (ACA titer 23 GPL units, or
presence of LAC, or both) or absent. Serum Hcy was
split into quartiles (limits: 12.5, 17.6, and 22.3 mol/L)
Table 1. Description of categoric variables
Variable Category Frequency (%)
Gender Male 234 (74)
Female 90 (26)
History of cardiovascular event Yes 29 (9)
No 295 (91)
Tobacco consumption Yes 75 (23)
No 249 (77)
Diabetes Yes 36 (11)
No 288 (89)
Hypertension Yes 266 (82)
No 58 (18)
Hyperlipidemia Yes 217 (67)
No 107 (33)
as were albumin and C-reactive protein. Tobacco con-
sumption was accounted for as currently smoking versus
nonsmoking. Hypertension and hyperlipidemia were de-
fined as above mentioned. Creatinine clearance was split
into two classes separated by its median. Proteinuria was
considered as positive if 1 g/day. Variables that were
split into quartiles were replaced by dummy variables in
the Cox model, which tested quartile 2 versus quartile 1,
quartile 3 versus quartile 1, and quartile 4 versus quar-
tile 1. Results are expressed as relative risk (RR) and
95% confidence interval (95% CI), with a P value testing
the null hypothesis: RR  1.
RESULTS
The patients were followed for a mean duration of 62
26 months. Their mean age was 48.1  16.3 years and
234 (74%) were men. Diabetes was present in 36 patients
(11%). A total of 75 patients (23%) were current smok-
ers and 29 patients (9%) had a past history of cardiovas-
cular disease.
Forty patients were treated with azathioprine or myco-
phenolate mofetil and prednisone, 17 received cyclospo-
rine and prednisolone regimen, and 277 patients received
azathioprine, cyclosporine, and prednisolone triple ther-
apy. A total of 301 patients had received polyclonal anti-
thymocyte globulins for induction.
Categoric variables are described in Table 1 and con-
tinuous variables are described in Table 2.
APAs
A total of 87 (26.8%) patients exhibited APAs: 73
ACAs (84%), 10 LAC (11.5%), and 4 both ACAs and
LAC (4.5%). Mean levels of ACAs in negative and posi-
tive patients were, respectively, 9  4.3 GPL units and
30.5  7.2 GPL units (P  0.0001). Transplant duration
was shorter (61 42 months vs. 79  48 months; P 
0.02) and hemodialysis duration before transplantation
was longer (33  41 months vs. 20  25 months; P 
0.02) in patients with APAs. Hepatitis C virus (HCV) (	)
patients were more prone to exhibit APAs (46% vs.
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Table 2. Description of continuous variables
Standard
Variable Mean deviation Median
Age years 48.1 16.3 51.00
Transplant duration months 67 49 62
Serum creatinine clearance mL/min 48 17 49
LDL cholesterol g/L 1.29 0.32 1.27
HDL cholesterol g/L 0.54 0.20 0.52
Total serum cholesterol g/L 2.17 0.46 2.21
Triglycerides g/L 1.61 1.14 1.37
Serum homocysteine lmol/L 19 7 17
Body mass index kg/m2 24.9 4.5 24
Systolic blood pressure mm Hg 137 20 140.00
Diastolic blood pressure mm Hg 82 11 83
C-reactive protein mg/L 4.8 4.2 3.00
Serum albumin g/L 42 4.5 43
Abbreviations are: LDL, low-density lipoprotein; HDL, high-density lipoprotein.
25.4%). Nevertheless, probably due to the low prevalence
of HCV (	) serology in our population, this difference
did not reach significance (P  0.08). Cytomegalovirus
(CMV) serology was positive in the same proportion of
patients with and without APAs (87% vs. 88%). We
found a slight, but significant, correlation between total
plasma Hcy (tHcy) concentration and ACAs titers (r 
0.26; P  0.036).
Atherosclerotic events
A total of 56 atherosclerotic events (17.2%) occurred
in 54 patients (four cerebrovascular disease; 36 coronary
heart disease; and 16 peripheral vascular disease). Of
the 45 patients (14%) who died, 21 (47%) were from
cardiovascular causes.
Atherosclerotic events occurred more frequently in
patients with APAs (33% vs. 9%; P 0.0003) and ACAs
levels were higher in patients who experienced athero-
sclerotic events (23.7  12.7 IU vs. 13.9  9.4 IU; P 
0.003).
In monovariate analysis, age (P 0.002), a past history
of cardiovascular disease (P 0.006), smoking status (P
0.07), diabetes mellitus (P  0.14), low creatinine clear-
ance (P  0.06), tHcy (P  0.0001), APAs (P  0.0003),
C-reactive protein (P  0.01) and low albumin concen-
tration (P  0.005) were associated with atherosclerotic
events.
We tested a possible interaction between APAs and
tHcy. RR for APAs was calculated separately for each
tHcy class. This interactions was minor because RR did
not change much with tHcy levels, and this did not mod-
ify the interpretation of the global RR.
After backward stepwise selection, the variables which
remained in the Cox proportional hazards model (i.e.,
which were linked to atherosclerotic events with P values
0.05) were APAs, age, history of atherosclerotic event,
current smoking, and serum Hcy. Gender and duration
since transplantation were kept in the model.
APAs were associated with an increased risk of ath-
erosclerotic events (RR, 2.82; 95% CI, 1.17 to 5.31).
Cox regression analysis also revealed that age above the
median (RR, 5.21; 95% CI, 1.67 to 17.13), a previous
history of cardiovascular disease (RR, 3.54; 95% CI, 1.57
to 10.43), and current smoking (RR, 2.17; 95% CI, 1.01
to 6.72) were risk factors for atherosclerotic events. Pa-
tients in the higher quartile of tHcy have a significantly
greater risk of atherosclerotic events than those in the
lowest quartile (RR, 4.01; 95% CI, 1.22 to 14.61).
RRs and their 95% CIs of atherosclerotic event for
each variable in the Cox model are displayed in Table
3, along with P values.
Pretransplant ACAs and risk of posttransplant
atherosclerotic event
Pretransplant sera were available for 142 patients.
Their mean follow-up was 56  32 months. Of these, 84
patients (59.1%) exhibited ACAs before transplantation
(group 1), whereas 58 (40.9%) had ACAs 23 GPL
units (group 2). ACAs remained present in 37 patients
(44%) of group 1 (group 1a) and disappeared in 47 pa-
tients (group 1b). Patients of group 1a and 1b only dif-
fered for dialysis duration (43  23 months vs. 19  12
months; P 0.02). Atherosclerotic events occurred more
frequently in patients with ACAs than in patients in
whom ACAs disappeared after transplantation (35.1%
vs. 10.6%; P  0.008). The incidence of atherosclerotic
events was similar in patients of group 2 and in patients
of group 1b (9.5% vs. 10.6%; P  0.27).
DISCUSSION
There is a high incidence of cardiovascular complica-
tions in the organ transplant population. In our cohort
of renal transplant recipients, the cumulative risk for de-
veloping atherosclerotic events was 3.5% within 1 year,
which is comparable to a previous report of our group
[3]. Both traditional and nontraditional cardiovascular
risk factors are very prevalent in our population and
contribute for this increased incidence of atherosclerotic
events. Nevertheless, we postulated that APAs, fre-
quently present in this population [17], may also contrib-
ute to this increased risk of atherosclerotic events. This
report represents the first study to date evaluating the
association between APAs and atherosclerotic events in
a large cohort of unselected renal transplant recipients
followed for a mean of 5 years for the development of
atherosclerotic events. The data presented herein show
that APAs antibodies represent an independent risk fac-
tor for atherosclerotic events, with a RR of 2.76 after
adjusting for other relevant clinical and biologic vari-
ables.
Some studies have focused on the role of APAs as a
risk factor for atherosclerotic events in different popula-
tions. Most of these studies have reported an increased
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Table 3. Cox model: Relative risks (RR) of cardiovascular event (atherosclorotic event) and 95% confidence intervals (95% CI)
RR before RRa after
Variable adjustment 95% CI adjustment 95% CI P value
Tobacco consumption No 1 — 1 — —
Yes 2.34 1.12 to 6.87 2.17 1.01 to 6.72 0.02
Age 50 years No 1 1
Yes 6.14 1.52; 18.45 5.21 1.67; 17.13 0.001
History of atherosclerotic event No 1 — 1 — —
Yes 3.91 1.42; 11.02 3.54 1.57; 10.43 0.002
Antiphospholipid antibodies No 1 1
Yes 2.99 1.27; 6.02 2.82 1.17; 5.31 0.008
Serum homocysteine lmol/L 12.5 (1st quartile) 1 — 1 —
12.5; 17.6 (vs. 1st quartile) 2.56 0.56; 12.57 2.18 0.41; 11.75 0.39b
17.6; 22.3 (vs. 1st quartile) 2.01 0.59; 9.03 1.39 0.22; 7.87 0.69b

21.3 (vs. 1st quartile) 4.89 1.37; 14.78 4.01 1.22; 14.61 0.018
aCox model is adjusted for duration since kidney transplant and gender
bNonsignificant at   5%
incidence of cardiovascular events in patients with APAs
[5–9]. APAs have been associated with both myocardial
infarction and noncardiac events, including stroke and
peripheral arterial disease. Nevertheless, because some
other studies have not confirmed these results, the role
of APAs remains controversial [10–13]. Discrepancies
in results are likely to be due, at least in part, to differ-
ences in study population, differences in test techniques,
and lack of statistical power. Another explanation is that
APAs can be induced in response to tissue necrosis that
occurs after ischemic injury. APAs could be a marker
of vascular damage rather than a risk factor for athero-
sclerotic events. However, both clinical [5, 7] and biologic
[18] evidence suggests that APAs precede the develop-
ment of acute atherosclerotic events. In our study, most
of patients were free of cardiovascular history. More-
over, our results were adjusted for past cardiovascular
disease and the mean interval between APAs detection
and atherosclerotic events was 21  11 months. Conse-
quently, our study clearly demonstrates that APAs both
precede and predict atherosclerotic events.
Our study confirms our previous results indicating that
most of APAs have been acquired in the pretransplant
period. More than half of patients with pretransplant
APAs lost these antibodies after transplantation. Inter-
estingly, only persistence of pretranplant APAs in the
posttransplant period is associated with an excess risk
of atherosclerotic events. Indeed, patients who never had
APAs and those who lost pretransplant APAs during the
posttranplant period seem to have a similar lower risk
of atherosclerotic events. This result is important for the
screening of APAs and the management of patients in
the transplant period. Prophylactic measures are proba-
bly not indicated in patients with APAs during the early
posttransplant period, whereas these treatments should
be discussed if APAs persist over months posttransplant.
Experimental data also support a role for APAs in
atherogenesis and thrombosis. During recent years, nu-
merous studies have provided evidence that immune
mechanisms are involved in atherosclerosis [19]. A grow-
ing body of evidence suggests that oxidation of LDL gen-
erates a wide variety of neoself determinants that lead
to cellular and humoral immune responses detectable in
atherosclerotic plaques. However, antibodies to oxidized
LDL can be detected in atherosclerotic patients and ex-
perimental animals [20]. However, some data suggest
that APAs and antibodies against oxidized LDL can
cross react [21]. Many, but not all, studies have demon-
strated that antibodies to oxidized LDL were indepen-
dent predictor of the progression of carotid atherosclero-
sis [22, 23]. It follows that APAs should be increased in
individuals with active atherogenesis and ongoing oxi-
dized LDL formation. Such antibodies may also be a
reflection of the underlying state of lipid peroxidation.
Indeed, a recent study demonstrated a good correlation
between the titer of ACA antibodies and the excretion of
F2 isoprostanes, a measure of in vivo lipid peroxidation
[24, 25]. APAs also promote thrombosis by multiple pos-
tulated mechanisms, including abnormal platelet aggre-
gation, decreased endothelial cell prostacyclin produc-
tion, antiendothelial cell antibodies, inhibition of the
thrombomodulin, protein C, protein S anticoagulant sys-
tem, and decreased fibrinolysis [18, 26, 27]. All together,
these data suggest different potential role of APAs in
atherogenesis and thrombosis.
It is unlikely that the observed association between
APAs and atherosclerotic events are due to chance or
an artifact of study design. Although an indirect associa-
tion can never be entirely excluded in an observational
study, such a bias remains unlikely. The causal nature of
the association between APAs and atherosclerotic events
is assessed in our study by temporality and strength, and
in literature by biologic plausibility and experimental
evidence. Nevertheless, there are some limitations to our
study. A selection bias cannot be excluded. Indeed, we
investigated the presence and significance of APAs a
long time after transplantation. However, APAs may
influence early outcomes in renal transplantation, espe-
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cially graft thrombosis [28]. Moreover, we only per-
formed one determination of APAs confirmed on a dif-
ferent sample collected after at least 4 weeks. APAs may
be transient and we cannot exclude that APAs disappear
in some patients.
We identified hyperhomocysteinemia as an indepen-
dent risk factor for atherosclerotic events in renal trans-
plant recipients. Our group had previously reported such
a result [16]. The present study also demonstrated a
slight, but significant, positive correlation between tHcy
concentration and ACA titers. Avivi et al [29] previously
reported a high prevalence of hyperhomocysteinemia in
patients with antiphospholipid syndrome. Nevertheless,
a direct relationship between tHcy and APAs had never
been reported. The mechanisms of such an association
remain hypothetical. Recent studies suggest that hyper-
homocysteinemia may enhance oxidative stress by both
increasing the generation of hydrogen peroxide, and,
selectively impairing the endothelial cell’s ability to de-
toxify hydrogen peroxide via an inhibition of the antioxi-
dant enzyme, glutathione peroxidase [30, 31]. Munts et al
[26] and Gruppo et al [27] recently reported a correlation
between the titer of ACA and the excretion of F2 iso-
prostanes, a marker of lipid peroxidation. Thus, APAs
formation may be induced by a tHcy-related oxidative
stress.
CONCLUSION
We found that a substantial proportion of renal trans-
plant recipients exhibit APAs. Moreover, our study
strongly suggests that the presence of APAs is an inde-
pendent cardiovascular risk factor in this population.
Prevention trials should be necessary to assess the effi-
cacy and safety of anticoagulation therapy in transplant
patients with APAs.
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